IRIS Accounts Production v26.2.0.496 11595354 Board of Directors 1.1.25 31.12.25 31.12.25 false true false false false true false Ordinary 0.0 Seed Ordinary 0.0 0.0 0.0 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh115953542024-12-31115953542025-12-31115953542025-01-012025-12-31115953542023-12-31115953542024-01-012024-12-31115953542024-12-3111595354ns15:EnglandWales2025-01-012025-12-3111595354ns14:PoundSterling2025-01-012025-12-3111595354ns10:Director12025-01-012025-12-3111595354ns10:PrivateLimitedCompanyLtd2025-01-012025-12-3111595354ns10:SmallEntities2025-01-012025-12-3111595354ns10:AuditExempt-NoAccountantsReport2025-01-012025-12-3111595354ns10:SmallCompaniesRegimeForDirectorsReport2025-01-012025-12-3111595354ns10:SmallCompaniesRegimeForAccounts2025-01-012025-12-3111595354ns10:AbridgedAccounts2025-01-012025-12-311159535412025-01-012025-12-3111595354ns10:OrdinaryShareClass12025-01-012025-12-3111595354ns10:OrdinaryShareClass22025-01-012025-12-3111595354ns10:OrdinaryShareClass1112025-01-012025-12-3111595354ns10:OrdinaryShareClass2122025-01-012025-12-3111595354ns10:Director32025-01-012025-12-3111595354ns10:Director42025-01-012025-12-3111595354ns10:Director52025-01-012025-12-3111595354ns10:Director72025-01-012025-12-3111595354ns10:Director82025-01-012025-12-3111595354ns10:Director92025-01-012025-12-3111595354ns10:RegisteredOffice2025-01-012025-12-3111595354ns5:CurrentFinancialInstruments2025-12-3111595354ns5:CurrentFinancialInstruments2024-12-3111595354ns5:ShareCapital2025-12-3111595354ns5:ShareCapital2024-12-3111595354ns5:SharePremium2025-12-3111595354ns5:SharePremium2024-12-3111595354ns5:FurtherSpecificReserve1ComponentTotalEquity2025-12-3111595354ns5:FurtherSpecificReserve1ComponentTotalEquity2024-12-3111595354ns5:RetainedEarningsAccumulatedLosses2025-12-3111595354ns5:RetainedEarningsAccumulatedLosses2024-12-3111595354ns5:IntangibleAssetsOtherThanGoodwill2025-01-012025-12-3111595354ns5:PlantMachinery2025-01-012025-12-3111595354ns5:FurnitureFittings2025-01-012025-12-3111595354ns5:ComputerEquipment2025-01-012025-12-3111595354ns5:WithinOneYear2025-12-3111595354ns5:WithinOneYear2024-12-3111595354ns10:OrdinaryShareClass12025-12-3111595354ns10:OrdinaryShareClass22025-12-3111595354ns5:RetainedEarningsAccumulatedLosses2024-12-3111595354ns5:SharePremium2024-12-3111595354ns5:FurtherSpecificReserve1ComponentTotalEquity2024-12-3111595354ns5:RetainedEarningsAccumulatedLosses2025-01-012025-12-31
REGISTERED NUMBER: 11595354 (England and Wales)












UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

FOR

NANOSYRINX LTD

NANOSYRINX LTD (REGISTERED NUMBER: 11595354)






CONTENTS OF THE FINANCIAL STATEMENTS
for the year ended 31 December 2025




Page

Company Information 1

Abridged Balance Sheet 2

Notes to the Financial Statements 4


NANOSYRINX LTD

COMPANY INFORMATION
for the year ended 31 December 2025







DIRECTORS: Dr J E Dancer
Dr B Anninga
Dr A G Johnson
Dr E Moses
Ms L E Edwardes-Jones
Dr H J Sanganee
T J Farrell


REGISTERED OFFICE: Unit 23b The Venture Centre
Sir Williams Lyons Road
University Of Warwick Science Park
Coventry
West Midlands
CV4 7EZ


REGISTERED NUMBER: 11595354 (England and Wales)


BANKERS: HSBC Bank Plc
London

NANOSYRINX LTD (REGISTERED NUMBER: 11595354)

ABRIDGED BALANCE SHEET
31 December 2025

2025 2024
as restated
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 186,827 116,683
Tangible assets 5 344,850 257,633
531,677 374,316

CURRENT ASSETS
Debtors 996,093 205,399
Cash at bank 6,687,915 9,612,590
7,684,008 9,817,989
CREDITORS
Amounts falling due within one year 613,297 195,638
NET CURRENT ASSETS 7,070,711 9,622,351
TOTAL ASSETS LESS CURRENT
LIABILITIES

7,602,388

9,996,667

CAPITAL AND RESERVES
Called up share capital 7 10 10
Share premium 8 17,900,574 16,219,417
Other reserves 8 1,685,067 1,222,240
Retained earnings 8 (11,983,263 ) (7,445,000 )
SHAREHOLDERS' FUNDS 7,602,388 9,996,667

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

NANOSYRINX LTD (REGISTERED NUMBER: 11595354)

ABRIDGED BALANCE SHEET - continued
31 December 2025


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

All the members have consented to the preparation of an abridged Balance Sheet for the year ended 31 December 2025 in accordance with Section 444(2A) of the Companies Act 2006.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 17 September 2026 and were signed on its behalf by:





T J Farrell - Director


NANOSYRINX LTD (REGISTERED NUMBER: 11595354)

NOTES TO THE FINANCIAL STATEMENTS
for the year ended 31 December 2025

1. STATUTORY INFORMATION

NanoSyrinx Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

The financial statements are presented in sterling which is the functional currency of the company and is rounded to the nearest £1.

Intangible assets
Patents are being amortised ay 6.5% per annum.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Laboratory equipment - 5 years straight line
Fixtures and fittings - Over 4 years
Computer equipment - Over 3 years

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Hire purchase and leasing commitments
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

NANOSYRINX LTD (REGISTERED NUMBER: 11595354)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2025

2. ACCOUNTING POLICIES - continued

Share based payments
Where share options are awarded, the fair value of the options at the date of grant is charged to the Income Statement over the vesting period. The total amount to be expensed over the vesting period is determined by reference to the fair value of the options granted at the date of the grant, excluding the impact of any non-market vesting conditions.

At each balance sheet date the company revises its estimates of the number of options that are expected to vest. It recognises the impact of the revision to the original estimates, if any, in the Income Statement. The credit entry is taken to reserves because the share options are equity-settled.

Where equity instruments are granted to persons other than employees, the Income Statement is charged with the fair value of goods and services received.

The share options are exercisable on the Ordinary share capital of the company.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 21 (2024 - 18 ) .

4. INTANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 January 2025 131,254
Additions 81,569
At 31 December 2025 212,823
AMORTISATION
At 1 January 2025 14,571
Amortisation for year 11,425
At 31 December 2025 25,996
NET BOOK VALUE

At 31 December 2025 186,827
At 31 December 2024 116,683

NANOSYRINX LTD (REGISTERED NUMBER: 11595354)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2025

5. TANGIBLE FIXED ASSETS
Totals
£   
COST
At 1 January 2025 437,527
Additions 202,750
At 31 December 2025 640,277
DEPRECIATION
At 1 January 2025 179,894
Charge for year 115,533
At 31 December 2025 295,427
NET BOOK VALUE
At 31 December 2025 344,850
At 31 December 2024 257,633

6. LEASING AGREEMENTS

Minimum lease payments under non-cancellable operating leases fall due as follows:
2025 2024
as restated
£    £   
Within one year 67,186 158,753

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2025 2024
value: as restated
£    £   
2,188,700 Ordinary 0.000001p 2 2
8,500,835 Seed Ordinary 0.000001p 8 8
10 10

The following fully paid shares were allotted during the year at a premium as shown below:

12,400 Ordinary shares of 0.000001p each at 0.000099p per share
787,036 Seed Ordinary shares of 0.000001p each at 215.999999p per share

NANOSYRINX LTD (REGISTERED NUMBER: 11595354)

NOTES TO THE FINANCIAL STATEMENTS - continued
for the year ended 31 December 2025

8. RESERVES
Retained Share Other
earnings premium reserves Totals
£    £    £    £   

At 1 January 2025 (7,445,000 ) 16,219,417 1,222,240 9,996,657
Deficit for the year (4,538,263 ) (4,538,263 )
Cash share issue - 1,681,157 - 1,681,157
Share based payments - - 462,827 462,827
At 31 December 2025 (11,983,263 ) 17,900,574 1,685,067 7,602,378

9. PENSION COMMITMENTS

The company operates a defined contribution pension scheme in respect of the directors and employees. The scheme and its assets are held by independent managers. The pension charge represents contributions due from the company and amounted to £186,758 (2024 - £114,476). At the year end there was a balance outstanding amounting to £51,899 (2024 - £24,806).

10. SHARE-BASED PAYMENT TRANSACTIONS

Certain individuals participate in an equity compensation plan. The plan is administered by the company's Board of Directors, which has the authority to determine which individuals are granted stock option awards. Upon exercise, the option awards are settled in shares and cannot be settled in cash. The cost of this scheme are disclosed in the preceding notes and have been made in order to match relevant expenditure and changes in equity.

A summary of stock option activity for company employees for the period ended 31 December 2025 is as follows:


Details
Number of
Options
Weighted Ave.
Exercise Price
Outstanding at 1 January 20251,262,020£0.023
Granted during the year181,800£0.000001
Exercised during the year(12,400)£0.0001
Forfeited during the year(17,900)£0.000085
Outstanding at 31 December 20251,413,520£0.0205

11. CONTROLLING PARTY

The directors do not consider there to be a single controlling or ultimate controlling party.